4 Oct 2021 15:10
4 October 2021
Grant of share options and PDMR notification
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 1 October 2021, the following Directors were granted share options over a total of 118,110 ordinary shares of0.1 pence each ("Ordinary Shares"), granted under the Clinigen Group Long Term Incentive Plan 2015. The options are nil cost options intended to vest on 1 October 2024 subject to the achievement of certain performance criteria.
Director/PDMR | Number of share options granted | Total number of share options now held |
| Total number of ordinary shares now held | Total number of ordinary shares (excluding share options) as % issued share capital |
Shaun Chilton | 118,110 | 732,074 |
| 330,044 | 0.25% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Shaun Chilton | |
2 | Reason for the notification | ||
a) | Position/status | Group Chief Executive Officer | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | 213800OBIKGI2JYYS227 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | Grant of Options | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | 118,110 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
118,110 Nil
| |
f) | Date of the transaction | 1 October 2021 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
-Ends-
For more information, please contact:
Clinigen Group plc | +44 (0) 1283 495010 |
Shaun Chilton, Chief Executive Officer Rob Fox, VP Investor Relations and Corporate Development | investors@clinigengroup.com |
Numis Securities Limited - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
James Black / Garry Levin / Freddie Barnfield | clinigen@Numis.com
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas | |
Consilium Strategic Communications Mary-Jane Elliott / Matthew Cole / Jessica Hodgson |
Tel: +44 (0) 20 3709 5700 clinigen@consilium-comms.com
|
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products company focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 120 countries.
For more information on Clinigen, please visit http://www.clinigen.com